25 results about "Compounding drugs" patented technology

The invention relates to the technical field of anti-enterovirus medicines, in particular to application of Enractevir in preparation of an anti-enterovirus medicine. According to the invention, efficient screening of candidate drugs is realized through a multi-channel virus reporting system based on a TAT trans-activation effect, and a small molecule compound drug Enractevir with a specific antiviral effect on enterovirus group A 71 and enterovirus group D 68 is obtained. Enractevir improves the interferon secretion level of host cells by inhibiting the activity of enterovirus 2A / 3C protease, thereby inhibiting virus replication and proliferation. Enractevir plays a role through double-target 2A / 3C protease, and the risk of virus drug resistance can be reduced. According to the technical scheme, the technical problem that in the prior art, specific drugs for the two kinds of enteroviruses are lacked can be solved, a standardized treatment scheme is provided for prevention and control of enterovirus related diseases in the global range, and the medicine has remarkable public health significance and wide application and popularization value.

The invention belongs to the technical field of medicine preparation, and particularly relates to an anti-HIV infection compound medicine microsphere composition, a medicine preparation and application. The invention firstly provides an anti-HIV (Human Immunodeficiency Virus) infection compound drug microsphere composition, which is composed of Cabotegravir, rilpivirine and at least one polylactic acid-glycolic acid copolymer, and comprises a first compound microsphere composition or a second compound microsphere composition, wherein one of the microsphere compositions is a co-coated microsphere formed by co-coating Cabotegravir and rilpivirine in the same microsphere; and the other microsphere composition is a mixture consisting of a microsphere for wrapping Cabotegravir and a microsphere for wrapping rilpivirine. The invention aims to provide a flexible preparation platform so as to optimize the long-acting treatment effect of the two anti-HIV drugs. For a composition form that one microsphere wraps two medicines, synchronous release and long-acting release of the two medicines are realized as much as possible; for another physically mixed composition form, independent regulation of release kinetics of a single drug is achieved as much as possible, so that the same administration cycle is achieved. The pharmaceutical preparation disclosed by the invention can be used for prevention before HIV exposure and long-term maintenance treatment of infected persons, and can be used for remarkably improving medication compliance and reducing the risk caused by virus drug resistance.

The invention relates to a combined application of a benzimidazole compound and a BCR-ABL1TKI inhibitor in preparation of a medicine for treating leukemia related diseases, and provides a combined application of the benzimidazole compound and the BCR-ABL1TKI inhibitor in preparation of a medicine for preventing or treating leukemia related diseases.

This invention provides a compound drug for treating melioidosis, its preparation method, and its application. The drug comprises active components of traditional Chinese medicine, a bioactive preparation, and a pharmaceutically acceptable carrier. The active components of traditional Chinese medicine are primarily extracts of Scutellaria baicalensis, Coptis chinensis, Fagopyrum dibotrys, and Polygonum cuspidatum. The bioactive preparation includes polymyxin B, homoserine lactonease, and recombinant human β-defensin 3. The components work synergistically to construct a comprehensive intervention system covering all pathological stages, including biofilm disruption, sterilization, anti-endotoxin activity, intracellular bacterial clearance, immune regulation, and tissue repair. This system can effectively disrupt bacterial biofilms, kill multidrug-resistant strains, neutralize endotoxins, and eliminate latent intracellular bacteria, addressing the core pain points of existing melioidosis treatments, such as strong drug resistance, significant toxic side effects, and high recurrence rates. The preparation process of this invention is carried out under low-temperature and sterile conditions throughout, which fully preserves the stability of the active ingredients, making it suitable for industrial production. The drug can be prepared in various dosage forms, covering all clinical subtypes of melioidosis, and possesses clinical application value and promising prospects for widespread application.

The invention discloses a network dynamics method and system of complex numbers and trigonometric functions for representing medicine vibration and rhythm effects and a storable medium thereof, and belongs to the field of biological medicine effect analysis. The method comprises the following steps: S1, establishing a network dynamics mathematical model of a complex number and a trigonometric function according to vibration and rhythmicity characteristics of medical action; s2, measuring the intensity of the observation index at different time points, and obtaining a time sequence effect curve of the observation index; s3, performing curve fitting on the time sequence effect curve obtained in the S2 based on the mathematical model established in the S1 to obtain a plurality of action parameters, and constructing a quantity-time curve or an effect-time curve based on the plurality of action parameters; and S4, performing statistical moment analysis on the quantity-time curve or the effect-time curve constructed in the S3, and analyzing action quantity-time-effect parameters to obtain the vibrativity, the rhythmicity and the network action rule of the medical action. The invention has breakthrough significance for developing new compound medicines and diagnosis and treatment equipment, and has huge potential economic benefits.

The invention relates to the field of traditional Chinese medicine compositions, and particularly discloses a traditional Chinese medicine composition for detoxifying, dredging collaterals, eliminating paste and stabilizing sugar and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 7 to 15g of rhizoma coptidis, 6 to 10g of wine-treated rhubarb, 15 to 30g of radix astragali seu hedysari, 12 to 15g of radix salviae miltiorrhizae, 12 to 20g of radix paeoniae rubra, 6 to 10g of radix bupleuri, 6 to 10 parts of herba artemisiae scopariae, 7 to 15 parts of fructus crataegi and 7 to 15 parts of pericarpium citri reticulatae. The detoxifying, collateral dredging, ointment eliminating and sugar stabilizing traditional Chinese medicine composition can achieve the effects of reducing blood sugar fluctuation and lipid deposition on the basis of achieving the effects of reducing blood sugar and improving the insulin resistance level, can effectively reduce the dosage of compound medicine for a patient so as to improve the compliance of the patient, is safe and effective, delays the occurrence of diabetes complicated diseases and complications, and has a wide application prospect. And the living quality of the patient is improved.

The invention relates to the technical field of polypeptide compound drugs, in particular to a polypeptide compound and a pharmaceutical composition and application thereof. The invention discloses a polypeptide compound. The polypeptide compound has a structural formula (XX), the polypeptide compound disclosed by the invention shows good osteogenic activity in vitro and has relatively good pharmacokinetic characteristics, so that the polypeptide compound has a potential application value in osteoporosis treatment.

The present application provides a 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole compound bulk drug, wherein the particle size D90 of the compound bulk drug is 70-5 μm. The present application also provides a composition comprising the bulk drug and an excipient. The bulk drug or the composition is used in the preparation of a drug for promoting the excretion of uric acid. The bulk drug of the present application can make the pharmaceutical composition comprising the same have better content uniformity and faster dissolution rate.

The application belongs to the technical field of medicine, and discloses the use of a composition targeting the intestinal flora-UCP1 axis in preventing and / or treating metabolic syndrome and complications thereof. Specifically, the application relates to the use of tea extract, panax notoginseng extract and dendrobium extract in combination as active ingredients in the treatment of metabolic syndrome and complications thereof, and the use of any two or more of tea extract, panax notoginseng extract and dendrobium extract as active ingredients in combination with other active ingredients and excipients in the preparation of a compound drug preparation for clinical use in a daily dosage of 0.001-2000 mg / kg body weight. The application has a synergistic effect, is used for treating metabolic syndrome and complications thereof, reduces the dosage of a single agent, improves the prevention and treatment effect, reduces side effects, lowers the cost, and meets the basic requirements of health economics.

The application discloses a compound polymyxin inhalation preparation, which is composed of a polymyxin polypeptide, an aminoglycoside antibiotic and a pharmaceutically acceptable auxiliary material. The molar ratio of the polymyxin polypeptide to the aminoglycoside antibiotic in the inhalation preparation is 1:20-1:80. Compared with single preparation or a compound preparation with a molar ratio of less than 1:20, the compound preparation with the molar ratio can significantly reduce lung toxicity and achieve a significant effect of clearing multiple drug-resistant bacteria in lung infection. The compound drug is delivered by using an inhalation liquid preparation dosage form, so that the total drug delivery efficiency of atomization inhalation is greatly improved, the median particle size of the drug is smaller, and the proportion of particles with a size of less than 5 microns is more than 55%, so that the drug is more easily inhaled into the lung to achieve an anti-infection treatment effect.

The invention provides a 3-(3, 5-dichloro-4-hydroxybenzoyl)-1, 1-dioxo-2, 3-dihydro-1, 3-benzothiazole compound bulk drug, and the particle size D90 of the compound bulk drug is 70 to 5 [mu] m. The invention also provides a composition which comprises the raw material medicine and an excipient. The raw material medicine or the composition is applied to preparation of medicines for promoting excretion of uric acid. According to the raw material medicine disclosed by the invention, the medicine composition containing the raw material medicine has relatively excellent content uniformity and relatively high dissolution rate.

The invention belongs to the technical field of biological medicines, and particularly relates to a composite medicinal preparation for treating diabetic retinopathy and a preparation method thereof. The traditional Chinese medicine composition comprises traditional Chinese medicine raw materials and auxiliary materials, the traditional Chinese medicine raw materials comprise the following components: an astragalus extract, a salvia miltiorrhiza water-soluble extract, a salvia miltiorrhiza fat-soluble extract, panax notoginseng saponins, a scutellaria baicalensis extract, a ginkgo leaf extract, a lycium barbarum polysaccharide extract and quercetin; the auxiliary materials comprise the following components: soybean lecithin, tween-80, PEG-40 hydrogenated castor oil, medium chain triglyceride oil, glycerol, vitamin E, Arabic gum, maltodextrin, microcrystalline cellulose, PVP K30, croscarmellose sodium and silicon dioxide. On the basis of conventional ophthalmic treatment, multiple components in the formula form a closed-loop cooperative multi-target intervention retina microenvironment, the problems of component dispersion and the like are solved through the combined process, and biocompatibility and compliance are both considered.

The application discloses a compound drug-loaded exosome for overcoming cancer TRAIL drug resistance and a preparation method thereof, relates to the technical field of compound nano-drug preparation, and comprises an engineered exosome and an interfering RNA targeting a natriuretic peptide receptor A gene, wherein the engineered exosome is derived from a cell capable of expressing a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and carries the TRAIL protein; the interfering RNA is loaded in the engineered exosome; and the engineered exosome and the interfering RNA synergistically act to silence the NPRA gene through the interfering RNA to overcome the drug resistance of cancer cells to TRAIL. The application can silence the NPRA gene and remodel the apoptosis sensitivity of tumor cells through multiple channels, thereby efficiently overcoming the TRAIL drug resistance.

It provides a consistent, safe and convenient method of mixing ingredients for injection. An adapter for connecting one or more storage containers to a syringe is described. The adapter includes a first port providing a connection with a first container volume, a second port providing a connection with a second container volume, and a third port providing a connection to a syringe. The adapter further includes a mixing channel extending from a first end to a second end in fluid communication with the third port. The mixing channel includes a serpentine path along at least a portion of its length. The mixing channel allows two components of a combination drug to mix through the mixing channel to form a combination drug. Also disclosed are systems including such adapters, methods of mixing two components of a combination drug through such adapters, and methods of manufacturing such adapters.

The present application provides a 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole compound bulk drug, wherein the particle size D90 of the compound bulk drug is 70-5 μm. The present application also provides a composition comprising the bulk drug and an excipient. The bulk drug or the composition is used in the preparation of a drug for promoting the excretion of uric acid. The bulk drug of the present application can make the pharmaceutical composition comprising the same have better content uniformity and faster dissolution rate.

The invention relates to the technical field of traditional Chinese medicine compound compatibility research, and discloses a compound medicine effect big data analysis method and system based on deep learning, and the method comprises the steps: obtaining multi-source heterogeneous data of a compound medicine, and generating a standardized data set; based on component relevance calculation, a medicine component interaction diagram is constructed; utilizing a heterogeneous graph attention network to extract graph features, and generating a multi-scale graph representation vector; inputting the multi-scale graph representation into a dynamic graph structure learning algorithm, and outputting a time-varying interaction mode; and predicting a synergistic effect index and an optimal ratio based on the learned interaction mode. According to the method, the technical problem of low compound drug effect prediction accuracy is solved, accurate modeling of a complex component relationship is realized, and a scientific basis is provided for rational design of compound drugs.

The application provides a pharmaceutical composition containing a 5alpha-reductase inhibitor, which comprises a peripheral vasodilator, a 5alpha-reductase inhibitor, a non-volatile solvent, a volatile solvent and water. The inventors have unexpectedly found that by adjusting the solvent system, not only can the greasy feeling and irritation of the pharmaceutical composition of the peripheral vasodilator and the 5alpha-reductase inhibitor be effectively reduced, but also the optimal absorption effect of the compound drug can be achieved, the drug absorption utilization rate is further improved, and the patient compliance is greatly improved.

This invention discloses a method for preparing a traditional Chinese medicine compound for treating rapid atrial fibrillation, comprising: extracting Coptis chinensis with phosphate buffer; acquiring optical data of the extract in real time and inputting it into a multi-channel convolutional neural network model; terminating extraction when the output comprehensive extraction efficiency index reaches a predetermined threshold to obtain Coptis chinensis extract; decocting Codonopsis pilosula, Polygonatum sibiricum, Rehmannia glutinosa, Paeonia lactiflora, Morus alba, Glycyrrhiza uralensis, Citrus medica, calcined dragon bone, calcined oyster shell, and Rosa rugosa; acquiring real-time concentration time-series data of tanshinone IIA, paeoniflorin, and glycyrrhizic acid in the decoction and inputting it into a long short-term memory neural network model; terminating decoction when the interaction effect parameter fluctuates within ≤±5% for three consecutive detection cycles to obtain a mixed decoction; combining the Coptis chinensis extract and the mixed decoction, concentrating to obtain a concentrated extract; and preparing the traditional Chinese medicine compound. This invention can improve the preparation efficiency and quality stability of traditional Chinese medicine compound drugs.

The invention relates to the technical field of ocean engineering antifouling materials, and particularly discloses a preparation method of a composite material for synergistically preventing barnacles from being attached to a hull. The method comprises the following steps: preparing a woven fabric with high density and smooth surface as a physical barrier layer, compounding a chitosan-modified drug-loaded microcapsule with biodegradable polyester to prepare a skin-core structure fiber layer with a slow release function, and finally compounding the two layers through a hot rolling microdot bonding process. According to the invention, a multi-stage protection system with a synergistic effect of a physical barrier and chemical slow release is constructed, controllable and long-acting release of the antifouling agent is realized, and the problems of sudden release of the antifouling agent and easy shedding of a coating in the prior art are effectively solved. The composite material has the advantages of being environmentally friendly, long in protection period, firm in combination and the like, and is suitable for barnacle attachment protection of ships and ocean facilities.

The invention belongs to the field of veterinary drugs, and particularly relates to a composite pharmaceutical composition for preventing and treating avian salmonella infection and application of the composite pharmaceutical composition. The composition comprises the following components in parts by weight: florfenicol, coptis chinensis and schisandra chinensis extract, vitamin C and prebiotics. Florfenicol and specific traditional Chinese medicines are combined and matched with sufficient vitamin C and prebiotics to form an antibacterial-protection-repair three-in-one synergistic system. On the premise of remarkably reducing the dosage of florfenicol, the compound can achieve a better clinical curative effect, relieve toxic and side effects and promote rapid rehabilitation of infected poultry, has obvious comprehensive advantages and is suitable for preparing a medicine for preventing and treating avian salmonellosis.

This invention relates to a jet microneedle delivery device capable of achieving controllable initial diffusion and precise targeted drug delivery, compositions for local tumor injection, drug-device combination products, and their use in the preparation of drugs for local tumor injection. The jet microneedle delivery device uses a conventional needle-free jet injection power source, combined with one or more microneedles to achieve diffusion and precise delivery. The composition includes a boron compound drug component, an immune adjuvant, and a drug carrier. Through a specially designed jet microneedle delivery device, boron compound radiotherapy drugs can be delivered locally to the tumor, avoiding the problems of traditional intravenous administration where drugs struggle to reach the tumor interior and surface, and where systemic toxicity or overdose radioactivity limits the maximum drug dose and therapeutic effect. The high-concentration local delivery of the composition not only improves the local therapeutic effect on the tumor but also effectively generates tumor-specific antibodies through neoantigens produced during treatment, assisted by the immune adjuvant.

The application belongs to the technical field of biological medicine, and particularly relates to a compound drug preparation for treating diabetic retinopathy and a preparation method thereof. The compound drug preparation is composed of traditional Chinese medicine raw materials and auxiliary materials. The traditional Chinese medicine raw materials comprise the following components: Astragalus extract, Danshen water-soluble extract, Danshen fat-soluble extract, Panax notoginseng total saponins, Huangqi extract, Ginkgo biloba leaf extract, Medlar polysaccharide extract and quercetin. The auxiliary materials comprise the following components: Soybean lecithin, Tween-80, PEG-40 hydrogenated castor oil, medium-chain triglyceride oil, glycerol, vitamin E, acacia gum, malt dextrin, microcrystalline cellulose, PVP K30, cross-linked sodium carboxymethyl cellulose and silicon dioxide. On the basis of conventional ophthalmic treatment, the application forms a closed-loop synergistic multi-target intervention retinal microenvironment through multiple components, solves the problems of component dispersion through a combination process, and takes into account biocompatibility and compliance.

The application discloses a compound polymyxin inhalation preparation, which is composed of a polymyxin polypeptide, an aminoglycoside antibiotic and a pharmaceutically acceptable auxiliary material. The molar ratio of the polymyxin polypeptide to the aminoglycoside antibiotic in the inhalation preparation is 1:20-1:80. Compared with single preparation or a compound preparation with a molar ratio of less than 1:20, the compound preparation with the molar ratio can significantly reduce lung toxicity and achieve a significant effect of clearing multiple drug-resistant bacteria in lung infection. The compound drug is delivered by using an inhalation liquid preparation dosage form, so that the total drug delivery efficiency of atomization inhalation is greatly improved, the median particle size of the drug is smaller, and the proportion of particles with a size of less than 5 microns is more than 55%, so that the drug is more easily inhaled into the lung to achieve an anti-infection treatment effect.

The application relates to the technical field of drug knowledge graph, and provides a knowledge graph construction system of a drug database, which comprises a data acquisition module, an analysis module, a graph module, a risk assessment module and a verification module; key characteristic data information and graph abnormal characteristic parameter information of target compound drugs of various compound structure types in the drug database are acquired; drug key characteristic factors and graph abnormal characteristic representation values are analyzed; whether the system operation conforms to the standard is determined through the graph module; if the standard is not met, the verification module is started based on the graph structure risk tendency type; and corresponding processing modes are adopted based on the determined reasons for not meeting the standard. Discrete drug data is converted into a calculable and explorable relationship network, a structured knowledge graph is provided for drug research and development and clinical research, and the system efficiency and precision are improved.

This invention belongs to the pharmaceutical field, specifically relating to a compound pharmaceutical preparation for treating chronic uric acid nephropathy and its application. This invention provides a compound pharmaceutical preparation for treating chronic uric acid nephropathy, which is a tablet composed of levocarnitine and trimetazidine in a certain proportion. The levocarnitine and trimetazidine compound preparation can significantly improve renal function in patients with chronic uric acid nephropathy and protect against kidney damage.